TRIBE; Tyrosine kinase inhibitor therapy in renal-cell carcinoma: Immune biomarker evaluation

被引：0
|
作者：
Villa, S. [1 ]
Pillai, M. [2 ]
Graham, D. [1 ]
Kilgour, E. [3 ]
Overton, N. [3 ]
Vasudev, N. [4 ,5 ]
Hughes, A. [6 ]
Walker, A. [1 ]
Dransfield, S. [1 ]
Thistlethwaite, F. [1 ]
机构：
[1] Christie NHS Fdn Trust, Expt Canc Med Team, Manchester, Lancs, England
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] Canc Res UK Manchester Inst, Clin & Expt Pharmacol Grp, Manchester, Lancs, England
[4] Leeds Inst Canc & Pathol, Leeds, W Yorkshire, England
[5] St Jamess Inst Oncol, Leeds, W Yorkshire, England
[6] Univ Manchester, Manchester, Lancs, England
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
10.1093/annonc/mdy315.008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
58TiP
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [1] Adjuvant therapy in renal cell carcinoma: Tyrosine kinase inhibitor versus immune checkpoint inhibitor
    Zhou, Qingbo
    Liu, Jianjiang
    Xie, Shaoqin
    MEDICINE, 2024, 103 (22) : E38329
  • [2] Determinants of neoadjuvant immune checkpoint inhibitor plus tyrosine kinase inhibitor therapy response in renal cell carcinoma
    Gu, L.
    Liang, Q.
    Zhang, X.
    Wang, B.
    ANNALS OF ONCOLOGY, 2024, 35 : S1507 - S1507
  • [3] IMMUNE STATUS AND IMMUNE THERAPY OF RENAL-CELL CARCINOMA
    BICHLER, KH
    KLEINKNECHT, S
    STROHMAIER, WL
    UROLOGIA INTERNATIONALIS, 1990, 45 (05) : 269 - 283
  • [4] ALTERNATING IMMUNE THERAPY IN RENAL-CELL CARCINOMA
    KASSUBEK, J
    WITZKE, O
    BONMANN, E
    MUSCH, E
    ONKOLOGIE, 1995, 18 (03): : 252 - 254
  • [5] IMMUNE THERAPY OF ADVANCED RENAL-CELL CARCINOMA
    MANSECK, A
    WIRTH, M
    UROLOGE-AUSGABE A, 1993, 32 (05): : 360 - 373
  • [6] Novel role of a tyrosine kinase inhibitor by reversion of immune suppression in renal cell carcinoma
    Seliger, B.
    Mueller, A.
    Giersberg, Corinna
    Handke, Diana
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Salvage immune checkpoint inhibitor (ICI) plus tyrosine kinase inhibitor (TKI) combination therapy for metastatic renal cell carcinoma (mRCC).
    Parikh, Anish B.
    Psutka, Sarah P.
    Yang, Yuanquan
    Collier, Katharine
    Miah, Abdul
    Li, Mingjia
    Mori-Vogt, Sherry
    Hinkley, Megan
    Orcutt, Delaney
    Trott, Elliott
    Gross, Evan
    Hussey, Duncan
    Kramer, Joel
    Oliva, Kaylee
    Mortazavi, Amir
    Monk, Paul
    Folefac, Edmund
    Clinton, Steven K.
    Yin, Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [8] SALVAGE IMMUNE CHECKPOINT INHIBITOR (IO) PLUS TYROSINE KINASE INHIBITOR (TKI) COMBINATION THERAPY FOR METASTATIC RENAL CELL CARCINOMA (MRCC)
    Parikh, Anish
    Psutka, Sarah
    Yang, Yuanquan
    Collier, Katharine
    Miah, Abdul
    Li, Mingjia
    Mori-Vogt, Sherry
    Hinkley, Megan
    Mortazavi, Amir
    Monk, Paul
    Folefac, Edmund
    Clinton, Steven
    Orcutt, Delaney
    Gross, Evan
    Hussey, Duncan
    Trott, Elliot
    Kramer, Joel
    Oliva, Kaylee
    Gore, John
    Schade, George
    Lin, Daniel
    Tykodi, Scott
    Hall, Evan
    Thompson, John
    Yin, Ming
    JOURNAL OF UROLOGY, 2021, 206 : E261 - E261
  • [9] Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
    Kwok, Christopher
    Khorasanchi, Adam
    Psutka, Sarah P.
    Hinkley, Megan
    Dason, Shawn
    Sundi, Debasish
    Yang, Yuanquan
    Yang, Yajing
    Verschraegen, Claire
    Gross, Evan E.
    Orcutt, Delaney
    Yin, Ming
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [10] Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma
    Ishihara, Hiroki
    Kondo, Tsunenori
    Fukuda, Hironori
    Yoshida, Kazuhiko
    Omae, Kenji
    Takagi, Toshio
    Iizuka, Junpei
    Kobayashi, Hirohito
    Tanabe, Kazunari
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2017, 47 (12) : 1175 - 1181
12345